



## Case Report

# Role of Erbium YAG laser in management of scar at donor site of split thickness skin grafting

Bharath Kumar Singh<sup>1</sup>, Ravi Kumar Chittoria<sup>1,\*</sup>

<sup>1</sup>Dept. of Plastic Surgery, Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanvantari Nagar, Puducherry, India



## ARTICLE INFO

### Article history:

Received 20-10-2022

Accepted 05-11-2022

Available online 15-05-2023

### Keywords:

Erbium

YAG

Laser

Scar

Donor site

skin grafting

## ABSTRACT

A variety of revision treatments available for managing different types of scars, including laser therapy, chemical peeling, cryotherapy, dermabrasion, soft tissue augmentation, intralesional steroid injection, and surgical excision. Rhytides, dyschromias, and specific kinds of scars are among the epidermal and dermal lesions that are successfully treated using erbium YAG lasers. In this study, the use of the Erbium YAG laser to treat scars at the site of skin grafting is highlighted.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprint@ipinnovative.com](mailto:reprint@ipinnovative.com)

## 1. Introduction

Erbium YAG lasers are devices in which the active ion in a matrix like YAG is the rare earth element Erbium (yttrium aluminium garnet). Human skin can be resurfaced using erbium YAG lasers with a wavelength of 2.9 m to cure melasma, deep rhytides, and acne scars. The Erbium YAG laser, which has a wavelength of 2940 nm and a strong absorption in water, can be used to precisely and superficially ablate tissue since it almost completely absorbs in a very thin layer of skin beneath the surface.<sup>1-3</sup> The donor areas for skin grafting typically heal by secondary intention, leaving a scar there. A innovative method to the treatment of scars is the use of ablative lasers based on the fractional approach.<sup>4,5</sup> This study highlights the role of Erbium YAG laser for the management of scar at the donor site of skin grafting.

## 2. Materials and Methods

The study was conducted in the department of plastic surgery in a tertiary care hospital. Informed consent was obtained from the subject under study. Scientific and ethical approval was taken from department scientific and ethical committee. The patient being reported is a 7 year female child who presented with history of accidental spillage of hot water soup on her while playing in the kitchen involving the chest, abdomen, axilla, left upper arm and forearm amounting to a total of about 20 % mixed 2<sup>nd</sup> degree and 3<sup>rd</sup> degree deep burns. Patient complains of severe burning, itching and pain. The patient was admitted and treated initially with intra venous fluids and sterile dressing. After 48 hours tangential excision and skin grafting was done. The donor site of skin grafting (thigh) healed in 3 weeks. To prevent abnormal scarring at the donor site of skin grafting, 6 sessions of Erbium YAG laser were given at 3 weeks interval (Figure 1). Before and after session of Erbium YAG laser the photographic documentation of donor site was done.

The laser machine used was Quanta Q1<sup>TM</sup> laser with the Twain handle delivering at 2940 nm wavelength laser

\* Corresponding author.

E-mail address: [drchittoria@yahoo.com](mailto:drchittoria@yahoo.com) (R. K. Chittoria).

after taking necessary safety precautions. We used 4 mm tip with a pulse width of 0.3 J/cm<sup>2</sup> and a fluence of 4. The overall procedure takes 20 to 25 minutes and the patient tolerated the procedure well. After the procedure the site was cooled for 5 minutes. The patient was advised to avoid direct sunlight exposure and to use sunscreen with >30 SPF. The patient was given regular 6 sessions at 3 weeks interval. There were no adverse effects noted except for post treatment initial erythema which resolved within 5 to 7 days spontaneously. Laser treatment was given on outpatient basis and patient was allowed to continue with activities of daily life.



**Fig. 1:** Erbium YAG laser session in progress at donor site (thigh) of skin grafting

### 3. Results

After a follow up period of 5 months no adverse effects were noted. The scar remained soft and supple and did not develop any abnormal scarring.

### 4. Discussion

A hypertrophic scar is a condition marked by fibrosis and disorganized skin fibroblast collagen deposition.<sup>6</sup> Gender, age, genetic predisposition, patient immunological responses, kind of damage, wound size and depth, anatomical placement, and mechanical tension on the wound are six major risk factors for the development of hypertrophic scars.<sup>7</sup> The imbalance between Extra Cellular Matrix (ECM) synthesis and breakdown during wound healing is thought to be the cause of hypertrophic scar development.<sup>8</sup> Scar management techniques include the use of silicone sheets, pressure garments, steroids, resection and radiation, and various botulinum toxin types. There isn't a single method that can effectively remove all scars. Recently, it was discovered that carbon dioxide and the Erbium YAG laser are secure and reliable scar control techniques.<sup>9,10</sup>

Clinically, it is commonly acknowledged that pulsed dye laser (PDL) therapy minimises the production of

hypertrophic scars primarily by reducing angiogenesis. According to reports, PDL increases the pliability and erythema of young scars by photothermolyzing tiny blood vessels.<sup>11</sup> Other hypotheses for the process by which PDL can be clinically effective in treating scars include decreased cellular activity brought on by laser-induced anoxia or collagen lysis brought on by laser-stimulated cytokine release.<sup>12</sup> Although CO<sub>2</sub> lasers have traditionally been used to treat scars, Erbium YAG lasers offer all the advantages, including effective and precise tissue ablation. The use of the 2940 nm Erbium YAG laser prevents the potential of heat necrosis and enables more precise tissue ablation because its depth of penetration is just one sixth that of CO<sub>2</sub> lasers.<sup>13</sup> The lack of need for recipient site anaesthetic due to little to no pain is one special benefit of employing the Erbium YAG laser.<sup>14</sup> Thus, the Erbium YAG laser provides the operator with convenience and also creates a reasonably blood-free environment for the specialist's easier surgery.

Other treatments, like as silicone sheets and compression clothing, are pricy and difficult to apply. The patient had to visit the hospital frequently for the laser therapy, though, which was a drawback.<sup>15</sup> In our study, Erbium YAG laser was found to be useful in preventing abnormal scarring at the donor site skin grafting. The limitation of the study is that it is based on single case. A large multicentric, randomized, controlled trials are suggested to substantiate the outcome of our study.

### 5. Conclusion

Erbium YAG laser is useful in prevention of formation of abnormal scarring at donor site of skin grafting.

### 6. Source of Funding

None.

### 7. Conflict of Interest

None.

### References

- Weinstein C. Computerized scanning erbium:YAG laser for skin resurfacing. *Dermatol Surg.* 1998;24(1):83–92.
- Kaufmann R, Hibst R. Pulsed Er:YAG and 308 UV excimer laser: an in vitro and in vivo study of skin ablative effects. *Laser Surg Med.* 1989;9(2):132–72.
- Walsh JT, Deutsch TF. Er:YAG laser ablation of tissue: measurement of ablation rates. *Laser Surg Med.* 1989;9(4):327–34.
- Jung JY, Jeong JJ, Roh HJ, Cho SH, Chung KY, Lee WJ. Early postoperative treatment of thyroidectomy scars using a fractional carbon dioxide laser. *Dermatol Surg.* 2011;37(2):217–40.
- Kim SG, Kim EY, Kim YJ, Lee SI. The efficacy and safety of ablative fractional resurfacing using a 2,940-nm Er:YAG laser for traumatic scars in the early posttraumatic period. *Arch Plast Surg.* 2012;39(3):232–9.
- Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies. *Mol Med.* 2011;17(1-2):113–38.

7. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: A review. *Plast Reconstr Surg.* 1999;104(5):1435–58.
8. Spyrou GE, Naylor IL. The effect of basic fibroblast growth factor on scarring. *Br J Plast Surg.* 2002;55(4):275–82.
9. Alster TS, Lewis AB, Rosenbach A. Laser scar revision: comparison of CO2 laser vaporization with and without simultaneous pulsed dye laser treatment. *Dermatol Surg.* 1998;24(12):1299–302.
10. Nehal KS, Levine VJ, Ross B. Comparison of high- energy pulsed carbon dioxide laser resurfacing and dermabrasion in the revision of surgical scars. *Dermatol Surg.* 1998;24(6):647–50.
11. Alster TS, Nanni CA. Pulsed dye laser treatment of hypertrophic burn scars. *Plast Reconstr Surg.* 1998;102:2190–5.
12. Dierickx CC, Casparian JM, Venugopalan V, Farinelli A, Anderson RR. Thermal relaxation of port-wine stain vessels probed in vivo: The need for 1-10-millisecond laser pulse treatment. *J Invest Dermatol.* 1995;105:709–23.
13. Kaufmann R, Greiner D, Kippenberger S, Bernd A. Grafting of in vitro cultured melanocytes onto laser-ablated lesions in vitiligo. *Acta Derm Venereol.* 1998;78(2):136–44.
14. Guerra L, Primavera G, Raskovic D, Pellegrini G, Golisano O, Bondanza S. Permanent repigmentation of piebaldism by erbium:YAG laser and autologous cultured epidermis. *Brit J Dermatol.* 2004;150(4):715–21.
15. Al-Hadidi N, Griffith JL, Al-Jamal, Hamzavi MS. Role of Recipient-site Preparation Techniques and Post-operative Wound Dressing in the Surgical Management of Vitiligo. *J Cutan Aesthet Surg.* 2015;8(2):79–87.

### Author biography

**Bharath Kumar Singh**, Senior Resident

**Ravi Kumar Chittoria**, Professor

**Cite this article:** Singh BK, Chittoria RK. Role of Erbium YAG laser in management of scar at donor site of split thickness skin grafting. *IP J Surg Allied Sci* 2023;5(1):30-32.